Hyperkalemia

Research suggests the use of additional treatment options, such as the mineralocorticoid receptor antagonist eplerenone, might prevent or delay overt diabetic nephropathy.

In a European study, approximately one-third of hospitalizations involving patients with recurrent hyperkalemia directly related to serum potassium elevation.

Final data from the CANVAS trials show that serious hyperkalemia is an uncommon occurrence.

Secondary results from the DAPA-HF trial suggest the sodium-glucose cotransporter 2 inhibitor may enable use of mineralocorticoid receptor antagonists in some patients with heart failure.

Recommendations that patients with chronic kidney disease be placed on low-potassium diets are based on poor-quality evidence.

Patients with a hyperkalemia-related hospitalization have significantly higher readmission rates over 12 months than patients with other reasons for hospitalization.

In a Swiss study of patients who made emergency department visits, significant proportions of those with acute kidney injury had hyperkalemia or hypokalemia.

Investigators observed a complex interaction between serum and fecal potassium, calcium, and magnesium during patiromer treatment in patients on hemodialysis.

In 3 trials of sodium zirconium cyclosilicate, serum bicarbonate increased regardless of CKD stage.